Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Complement factor B inhibitor plus prednisone and cyclophosphamide for relapsed or refractory C3d-positive warm autoimmune hemolytic anemia
ChiCTR2600135106Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Sep 2026
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of prednisone and cyclophosphamide in warm autoimmune hemolytic anemia (wAIHA), sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Objective response rate at 8 weeks. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
prednisonecyclophosphamide
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)
Beyond the preview
Go deeper on ChiCTR2600135106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135106.